Organizaciones instan a participar en consulta pública sobre nuevas técnicas genéticas y trigo editado Warnings are issued regarding ...

Biotech companies could add growth to your portfolio -- and in some cases, at a bargain price. It’s a great idea to select tomorrow's potential winners and hold on as their stories unfold. If you're ...

This biotech company has a track record of commercializing products and delivering growth. It also has strengths in research and development. When you think of biotech companies, you may think of ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

Unnatural Products is proving to be a natural at securing partnerships, this time linking up with Novartis in a deal that could garner up to $1.7 billion in biobucks. Novartis is shelling out $100 ...

Welcome to Fierce Biotech's fifth annual layoff tracker, a resource designed to keep pace with the sector's steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...

EyePoint (EYPT), Janux (JANX), Kyverna (KYTX), and Viking (VKTX) have analyst targets implying 179% to 384% upside. Janux and Kyverna hold the highest upside projections at 384% and 308% respectively, ...

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...

A prominent cancer scientist is uprooting his Harvard University lab of two decades and moving it to Texas. A laid-off expert on aging abandoned academia for a more secure municipal research job in ...